⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LIMN News
Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
globenewswire.com
LIMN
Form 8-K
sec.gov
LIMN
LIMNW
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
globenewswire.com
LIMN
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
globenewswire.com
LIMN
Form 8-K
sec.gov
LIMN
LIMNW
Form 8-K
sec.gov
LIMN
LIMNW
Form 8-K
sec.gov
LIMN
LIMNW
Form 8-K
sec.gov
LIMN
LIMNW
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
globenewswire.com
LIMN
Form 8-K
sec.gov
LIMN
LIMNW